A digital health investment company was launched by a leading pharmaceutical company in 2016. The firm focuses on the digital health space and invest in companies that use data and intelligence derived from data to solve important healthcare problems. The firm’s investments range dependent on the opportunity and focus mainly on Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to investing globally.
The firm focuses on digital health technologies and solutions that aim to improve the quality and the delivery of patient care. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data, and is interested in technology with machine-learning applications. Based on all the criteria, the firm is indication agnostic.
The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.
If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply